Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer

This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition

Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’

Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA

Granules India posts Q4 FY25 PAT at Rs. 152 Cr

The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility

Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification

Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs

Lupin to present Phase 1 Data on LNP7457 at ASCO Annual Meeting 2025

Akums reports Q4 FY25 with 12.4% revenue growth

Akums invested Rs. 272 crore in capital expenditure during FY25

Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr

The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25

Lupin and SteinCares ink agreement for Ranibizumab in Latin America

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth

Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP

Allopurinol is used to prevent or lower high uric acid levels in the blood